Completed PHASE1 INTERVENTIONAL 1-arm NCT04973826

Study to Assess the Pharmacokinetics, Safety and Tolerability of Aztreonam-Avibactam in Healthy Chinese Participants.

A PHASE I, SINGLE CENTER, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM ADMINISTERED AS SINGLE AND REPEATED INTRAVENOUS DOSES IN HEALTHY CHINESE PARTICIPANTS

Sponsor: Pfizer

Conditions Healthy

Interventions Aztreonam-Avibactam

Updated 6 times since 2021 Last updated: Sep 9, 2022 Started: Aug 20, 2021 Primary completion: Sep 27, 2021 Completion: Sep 27, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Pfizer leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Aug 2023 — Jul 2024 [monthly]

Completed PHASE1
Nov 2021 — Aug 2023 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Sep 2021 — Oct 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Aug 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China